Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. 2012

Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. jli22@partners.org

HIV-1 resistance testing was performed in 47 antiretroviral (ARV)-treated subjects with low-level viremia (LLV) of <1,000 copies/ml. The median viral load was 267 copies/ml. In those with ≥2 LLV episodes, 44% accumulated additional resistance mutations. Fewer active ARVs and longer elapsed time were associated with an increased risk of resistance accumulation after controlling for adherence and viral load. Virologic failure followed 16% of LLV time points. Strategies for early intervention after LLV episodes should be further studied.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014766 Viremia The presence of viruses in the blood. Viremias
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D059645 Mutation Rate The number of mutations that occur in a specific sequence, GENE, or GENOME over a specified period of time such as years, CELL DIVISIONS, or generations. Mutation Frequency,Frequencies, Mutation,Frequency, Mutation,Mutation Frequencies,Mutation Rates,Rate, Mutation,Rates, Mutation
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
September 2005, Journal of acquired immune deficiency syndromes (1999),
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
January 2012, PloS one,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
May 2010, The Journal of infectious diseases,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
October 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
October 2006, The Journal of infectious diseases,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
September 2005, Journal of acquired immune deficiency syndromes (1999),
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
August 2011, The Journal of infectious diseases,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
August 2004, AIDS patient care and STDs,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
January 2021, AIDS research and human retroviruses,
Jonathan Z Li, and Sebastien Gallien, and Tri D Do, and Jeffrey N Martin, and Steven Deeks, and Daniel R Kuritzkes, and Hiroyu Hatano
August 2008, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!